317 related articles for article (PubMed ID: 30940296)
1. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.
Chen MM; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):175-185. PubMed ID: 30940296
[TBL] [Abstract][Full Text] [Related]
2. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
4. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
Lazaridis N; Tsochatzis E
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
[TBL] [Abstract][Full Text] [Related]
5. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
[TBL] [Abstract][Full Text] [Related]
6. A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).
Povsic M; Oliver L; Jiandani NR; Perry R; Bottomley J
Pharmacol Res Perspect; 2019 Jun; 7(3):e00485. PubMed ID: 31149341
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
8. State of the art: treatment of nonalcoholic steatohepatitis.
Pearlman M; Loomba R
Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
11. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Golabi P; Bush H; Younossi ZM
Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic landscape of non-alcoholic steatohepatitis.
Perazzo H; Dufour JF
Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
14. Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y; Yoneda M
J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
[TBL] [Abstract][Full Text] [Related]
15. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis.
Tan CH; Al-Kalifah N; Lee WJ; Ser KH; Lee YC; Chen JC
Asian J Surg; 2019 Jan; 42(1):203-208. PubMed ID: 29804707
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease: new treatments.
Hardy T; Anstee QM; Day CP
Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
[TBL] [Abstract][Full Text] [Related]
17. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Mathews SE; Kumar RB; Shukla AP
Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological management of nonalcoholic fatty liver disease.
Barb D; Portillo-Sanchez P; Cusi K
Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
[TBL] [Abstract][Full Text] [Related]
20. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]